Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/la-malattia-di-beh-et-sNBySeXyuh
References (22)
-
D. Mendes, M. Correia, M. Barbedo, Teresa Vaio, M. Mota, O. Gonçalves, J. Valente (2009)
Behçet's disease--a contemporary review.Journal of autoimmunity, 32 3-4
-
Y. Cho, Whal Lee, Sang-Il Choi, H. Jae, J. Chung, Jae Park (2008)
Cardiovascular Behcet Disease: The Variable Findings of Rare Complications With CT Angiography and Conventional Angiography and Its Interventional ManagementJournal of Computer Assisted Tomography, 32
-
G. Hatemi, A. Silman, D. Bang, B. Bodaghi, A. Chamberlain, A. Gül, M. Houman, I. Kötter, I. Olivieri, C. Salvarani, P. Sfikakis, A. Siva, M. Stanford, N. Stübiger, S. Yurdakul, H. Yazıcı (2008)
Management of Behçet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behçet diseaseAnnals of the Rheumatic Diseases, 68
-
J. Ricart, A. Vayá, J. Todolí, J. Calvo, P. Villa, A. Estellés, F. España, M. Santaolaria, D. Corella, J. Aznar (2006)
Thrombophilic risk factors and homocysteine levels in Behçet’s disease in eastern Spain and their association with thrombotic eventsThrombosis and Haemostasis, 95
-
C. Salvarani, N. Pipitone, M. Catanoso, L. Cimino, B. Tumiati, P. Macchioni, G. Bajocchi, I. Olivieri, L. Boiardi (2007)
Epidemiology and clinical course of Behçet's disease in the Reggio Emilia area of Northern Italy: a seventeen-year population-based study.Arthritis and rheumatism, 57 1
-
H. Yanagihori, N. Oyama, Koichiro Nakamura, N. Mizuki, K. Oguma, F. Kaneko (2006)
Role of IL-12B promoter polymorphism in Adamantiades-Behcet's disease susceptibility: An involvement of Th1 immunoreactivity against Streptococcus Sanguinis antigen.The Journal of investigative dermatology, 126 7
-
奥貫 陽子 (2007)
Proteomic surveillance of autoimmunity in Behcet's disease with uveitis : selenium binding protein is a novel autoantigen in Behcet's disease -
Tuncay Sarican, H. Ayabakan, S. Turkmen, V. Kalaslıoğlu, Fehmi Baran, N. Yenice (2007)
Homocysteine: an activity marker in Behçet's disease?Journal of dermatological science, 45 2
-
Colliri midriatici ed iniezioni locali di corticosteroidi possono rendersi necessari nella fase acuta dell'uveite, per prevenire la formazione di sinechie -
Mathilde Menthon, M. Lavalley, C. Maldini, L. Guillevin, A. Mahr (2009)
HLA-B51/B5 and the risk of Behçet's disease: a systematic review and meta-analysis of case-control genetic association studies.Arthritis and rheumatism, 61 10
-
K. Suzuki, N. Suzuki (2004)
Behçet diseaseClin Exp Med, 4
-
G. Hatemi, A. Silman, D. Bang, B. Bodaghi, A. Chamberlain, A. Gül, M. Houman, I. Kötter, I. Olivieri, C. Salvarani, P. Sfikakis, A. Siva, M. Stanford, N. Stübiger, S. Yurdakul, H. Yazici (2008)
EULAR recommendations for the management of Behçet diseaseAnnals of the Rheumatic Diseases, 67
-
E. Alpsoy, C. Zouboulis, G. Ehrlich (2007)
Mucocutaneous Lesions of Behçet's DiseaseYonsei Medical Journal, 48
-
B. Weichsler, F. Davatchi, Y. Mizushima, M. Hamza, N. Dilşen, E. Kansu, H. Yazici, C. Barnes, M. Chamberlain, D. James, T. Lehner, J. O'duffy, A. Rigby, J. Gregory, A. Silman (1975)
[Criteria of diagnosis of Behcet's disease].La Tunisie medicale, 53 3
-
Le manifestazioni cutanee , specialmente l'eritema nodoso, rispondono in modo soddisfacente alla COLCHICINA 1 -1.5 mg/die al DAPSONE 100 mg/die ed ai corticosteroidi -
H. Behçet (1938)
Considerations sur le lésions aphteuses de la bouche et des parties génitales ainsi que sur les manifestations oculaires d’origine probablement parasitaire et observations concernant leur foyer d’infectionBull Soc Fr Dermatol Syph, 45
-
I. Krause, A. Weinberger (2008)
Behçet’s diseaseCurr Opin Rheumatol, 20
-
J. Karasneh, A. Gül, W. Ollier, A. Silman, Jane Worthington (2005)
Whole-genome screening for susceptibility genes in multicase families with Behçet's disease.Arthritis and rheumatism, 52 6
-
U. Rauch, Y. Nemerson (2000)
Tissue factor, the blood, and the arterial wall.Trends in cardiovascular medicine, 10 4
-
B. Furie, B. Furie (2008)
Mechanisms of thrombus formation.The New England journal of medicine, 359 9
-
V. Henn, J. Slupsky, M. Gräfe, I. Anagnostopoulos, R. Förster, G. Müller‐Berghaus, R. Kroczek (1998)
CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cellsNature, 391
-
H. Behcet (1937)
UBER REZIDIVERENDE APHTHOSE DURCH EIN VIRUS VERURSACHTE GESCHWURE AM MUND, AM AUGE UND AN DEN GENITALIEN, 105
- Publisher
- Springer Journals
- Copyright
- Copyright © 2010 by Springer-Verlag Italia
- Subject
- Medicine & Public Health; Orthopedics
- ISSN
- 0390-7368
- eISSN
- 1592-7113
- DOI
- 10.1007/s10261-010-0005-z
- Publisher site
- See Article on Publisher Site
Abstract
Behçet’s disease (BD) is a vasculitis mainly affecting populations living along the ancient “Silk Route”, with a prevalence of 10–400 cases every 100.000 persons. It is associated with the histocompatibility antigen HLAB51 and is driven by T cell activation. Clinically, BD is characterised by recurrent episodes of oral ulcers, genital ulcers, skin lesions, eye lesions, arthritis, thrombophlebitis, and, less commonly, gastrointestinal, neurological and pulmonary involvement. Superficial and deep thrombophlebitis are the most common vascular features of BD. They are due to inflammation of the vessel wall. Arteries, which are much less commonly involved, may develop aneurysms or occlusions. BD therapy is based on the following agents: corticosteroids, azathioprine, cyclosporine A, colchicine, methotrexate, cyclophosphamide and TNF antagonists. The treatment should be tailored to the individual patient according to type and severity of involvement. Anticoagulant and antiplatelet agents should not be used in the therapy of BD thrombosis.
Journal
Archivio di Ortopedia e Reumatologia – Springer Journals
Published: Jan 10, 2011